No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
Dexamethasone / therapeutic use
-
Humans
-
Multiple Myeloma* / drug therapy
-
Neoplasm Recurrence, Local / chemically induced
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasms, Plasma Cell*
-
Thalidomide / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Thalidomide
-
Dexamethasone
-
isatuximab
Grants and funding
Funding: Sanofi funded this sub-analysis of the ICARIA-MM and IKEMA studies. Medical writing support was provided by John Clarke, PhD, and Camile Semighini Grubor, PhD, on behalf of Elevate Medical Affairs, contracted by Sanofi for publication support services.